Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Outsourcing

- PMLiVE

Takeda begins development of COVID-19 plasma therapy

Drug will harness the antibodies of recovered coronavirus patients

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

Raising awareness and encouraging support on Rare Disease Day 2020

Rare Disease Day takes place on 29 February around the world

- PMLiVE

Takeda buys coeliac disease partner PvP Biologics after phase 1 win

Deal includes upfront payment plus up to $330m in milestones

- PMLiVE

BMS scores first oesophageal cancer nod for Opdivo in Japan

Approval in Japan comes before US okay

- PMLiVE

Astellas files new application for expanded use of roxadustat in Japan

Aims for use in anaemia associated with CKD in non-dialysis patients

- PMLiVE

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Was seeking approval in moderate-to-severe ulcerative colitis

- PMLiVE

UK is a leader in early clinical research but falls in later study stages, says ABPI

The UK faces challenges to stay competitive in clinical research globally

Novartis day

Novartis changes focus in Shanghai from early research to drug development

Swiss pharma switches focus of $1bn R&D institute

- PMLiVE

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

First wave of new molecular entities has potential to generate 14 approvals

- PMLiVE

Sandoz expands into Japan with €400m Aspen deal

Will gain presence in third largest generics market in the world

- PMLiVE

Takeda’s dengue vaccine seems safe with no prior virus exposure

Appears unaffected by serious safety issue affecting Sanofi rival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links